Differences in CYP2C9 genotype and enzyme activity between Swedes and Koreans of relevance for personalized medicine: Role of ethnicity, genotype, smoking, age, and sex

OMICS A Journal of Integrative Biology

Volumn 19, Issue 6, 2015, Pages 346-353

  Hatta, Fazleen H M ^a,b   Lundblad, Mia ^a   Ramsjo, Margareta ^a   Kang, Ju Hee ^c   Roh, Hyung Keun ^d   Bertilsson, Leif ^a   Eliasson, Erik ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c Inha University School of Medicine   (South Korea)

^d Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CAFFEINE; CYTOCHROME P450 2C9; DEBRISOQUINE; LOSARTAN; OMEPRAZOLE; QUININE; CYTOCHROME P450 3A;

ADULT; AGE; ALLELE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KOREAN (PEOPLE); MALE; NORMAL HUMAN; PERSONALIZED MEDICINE; PHENOTYPE; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SMOKING; SWEDE (PEOPLE); GENETICS; KOREA; METABOLISM; MULTIVARIATE ANALYSIS; PROCEDURES; YOUNG ADULT;

ADULT; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRECISION MEDICINE; SMOKING; YOUNG ADULT;

EID: 84930577932     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2015.0022     Document Type: Article

References (57)

1. Aklillu E, Carrillo J, Makonnen E, Bertilsson L, and Ingelman- Sundberg M. (2003). Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol 59, 533-536.
2. Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, and Ingelman-Sundberg M. (2014). High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS 18, 446-453.
3. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman-Sundberg M. (2002). Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12, 375-383.
4. Bae JW, Kim HK, Kim JH, et al. (2005). Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60, 418-422.
5. Bazan NS, Sabry NA, Rizk A, Mokhtar S, and Badary OA. (2014). Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: Role of gene polymorphism. Ir J Med Sci 183, 161-172.
6. Cabaleiro T, Roman M, Ochoa D, et al. (2013). Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Drug Metab Dispos 41, 224-229.
7. Chen Y, Ferguson SS, Negishi M, and Goldstein JA. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308, 495-501.
8. Christensen M, Andersson K, Dalen P, et al. (2003). The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73, 517-528.
9. Dandara C, Huzair F, Borda-Rodriguez A, et al. (2014). H3Africa and the African life sciences ecosystem: Building sustainable innovation. OMICS 18, 733-739.
10. Dang MT, Hambleton J, and Kayser SR. (2005). The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39, 1008-1012.
11. Degawa M, Stern SJ, Martin MV, et al. (1994). Metabolic activation and carcinogen-DNA adduct detection in human larynx. Cancer Res 54, 4915-4919.
12. Dickmann LJ, Rettie AE, Kneller MB, et al. (2001). Identification and functional characterization of a new CYP2C9 variant (CYP2C9∗5) expressed among African Americans. Mol Pharmacol 60, 382-387.
13. Diczfalusy U, Miura J, Roh HK, et al. (2008). 4 beta- Hydroxycholesterol is a new endogenous CYP3A marker: Relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18, 201-208.
14. Djordjevic N, Carrillo J, Roh H, et al. (2012). Comparison of Nacetyltransferase- 2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 52, 1527-1534.
15. Djordjevic N, Carrillo J, van den Broek M, et al. (2013). Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. Drug Metab Pharmacokinet 28, 93-97.
16. Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, and Aklillu E. (2011). Sex and CYP3A5 genotype influence total CYP3A activity: High CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 11, 130-137.
17. Ghotbi R, Christensen M, Roh H, Ingelman-Sundberg M, Aklillu E, and Bertilsson L. (2007). Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotypephenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63, 537-546.
18. Giri AK, Khan NM, Grover S, et al. (2014). Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics 15, 1337-1354.
19. Greenblatt DJ, and von Moltke LL. (2005). Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45, 127-132.
20. Gross AS, Bridge S, and Shenfield GM. (1999). Pharmacokinetics of tolbutamide in ethnic Chinese. Br J Clin Pharmacol 47, 151-156.
21. Han EH, Kim HG, Choi JH, et al. (2012). Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/ enhancer-binding protein beta activation. Mol Nutr Food Res 56, 797-809.
22. Hatta FH, Teh LK, Hellden A, et al. (2012). Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A> T and the losartan metabolism phenotype in Swedes. Eur J Clin Pharmacol 68, 1033-1042.
23. He SM, Zhou ZW, Li XT, and Zhou SF. (2011). Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 18, 667-713.
24. Hidaka M, Nagata M, Kawano Y, et al. (2008). Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Biosci Biotechnol Biochem 72, 406-411.
25. Imai J, Ieiri I, Mamiya K, et al. (2000). Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus. Pharmacogenetics 10, 85-89.
26. Izzo AA. (2005). Herb-drug interactions: An overview of the clinical evidence. Fundam Clin Pharmacol 19, 1-16.
27. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, and Goldstein JA. (2001). Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11, 803-808.
28. Kim MJ, Nafziger AN, Kashuba AD, et al. (2006). Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin. Eur J Clin Pharmacol 62, 431-436.
29. Kimmel SE, French B, Kasner SE, et al. (2013). A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369, 2283-2293.
30. Kimura Y, Ito H, and Hatano T. (2010). Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull 33, 1977-1982.
31. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, and Goldstein JA. (2003). Losartan and E3174 pharmacokinetics in cytochrome P450 2C9∗1/∗1, ∗1/∗2, and ∗1/∗3 individuals. Pharmacotherapy 23, 720-725.
32. Lee VW, You JH, Lee KK, Chau TS, Waye MM, and Cheng G. (2005). Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis 20, 33-38.
33. Llerena A, Alvarez M, Dorado P, et al. (2014). Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain. Pharmacogenomics J 14, 229-234.
34. Luckert C, Ehlers A, Buhrke T, Seidel A, Lampen A, and Hessel S. (2013). Polycyclic aromatic hydrocarbons stimulate human CYP3A4 promoter activity via PXR. Toxicol Lett 222, 180-188.
35. McCrea JB, Lo MW, Furtek CI, et al. (1996). Ketoconazole does not effect the systemic conversion of losartan to e-3174. Clin Pharmacol Ther 59, 44-44.
36. Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. Plos One 8, e67946.
37. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, and Tashiro N. (2000). Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 22, 230-232.
38. Okura T, Ibe M, Umegaki K, Shinozuka K, and Yamada S. (2010). Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 33, 255-259.
39. Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, and Bertilsson L. (2010). CYP2C19 activity comparison between Swedes and Koreans: Effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 66, 871-877.
40. Rettie AE, and Jones JP. (2005). Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45, 477-494.
41. Sandberg M, Johansson I, Christensen M, Rane A, and Eliasson E. (2004). The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos 32, 484-489.
42. Scordo M, Aklillu E, Yasar U, Dahl M, Spina E, and Ingelman- Sundberg M. (2001). Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52, 447-450.
43. Si D, Wang Y, Zhou YH, et al. (2009). Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos 37, 629-634.
44. Sica DA, Gehr TW, and Ghosh S. (2005). Clinical pharmacokinetics of losartan. Clin Pharmacokinet 44, 797-814.
45. Srinivas NR. (2013). Cranberry juice ingestion and clinical drug-drug interaction potentials; Review of case studies and perspectives. J Pharm Pharm Sci 16, 289-303.
46. Stearns RA, Chakravarty PK, Chen R, and Chiu SH. (1995). Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 23, 207-215.
47. Stergiopoulos K, and Brown DL. (2014). Genotype-guided vs clinical dosing of warfarin and its analogues: Meta-analysis of randomized clinical trials. JAMA Intern Med 174, 1330-1338.
48. Takahashi H, Wilkinson GR, Nutescu EA, et al. (2006). Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African- Americans. Pharmacogenet Genomics 16, 101-110.
49. Tatsuno SY, and Tatsuno EM. (2014). Does ethnicity play a role in the dosing of warfarin in Hawai'i? Hawaii J Med Public Health 73, 76-79.
50. Teh LK, Langmia IM, Fazleen Haslinda MH, et al. (2012). Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9∗3 among patients on warfarin. J Clin Pharm Ther 37, 232-236.
51. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, and Borlak J. (2006). Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 114, 1655-1661.
52. Wadelius M. (2014). Warfarin pharmacogenetics: It matters if you're black or white. Blood 124, 2171.
53. Wadelius M, Sorlin K, Wallerman O, et al. (2004). Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4, 40-48.
54. Wang YH, Pan PP, Dai DP, et al. (2014). Effect of 36 CYP2C9 variants found in the Chinese population on losartan metabolism in vitro. Xenobiotica 44, 270-275.
55. Wells PS, Holbrook AM, Crowther NR, and Hirsh J. (1994). Interactions of warfarin with drugs and food. Ann Intern Med 121, 676-683.
56. Yasar U, Aklillu E, Canaparo R, et al. (2002a). Analysis of CYP2C9∗5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 58, 555-558.
57. Yasar U, Forslund-Bergengren C, Tybring G, et al. (2002b). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71, 89-98.